Moderna (MRNA) Net Margin (2017 - 2025)
Historic Net Margin for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to 19.69%.
- Moderna's Net Margin fell 203800.0% to 19.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 139.61%, marking a year-over-year decrease of 952700.0%. This contributed to the annual value of 110.04% for FY2024, which is 412100.0% down from last year.
- According to the latest figures from Q3 2025, Moderna's Net Margin is 19.69%, which was down 203800.0% from 580.99% recorded in Q2 2025.
- Over the past 5 years, Moderna's Net Margin peaked at 67.51% during Q4 2021, and registered a low of 899.07% during Q1 2025.
- In the last 5 years, Moderna's Net Margin had a median value of 4.24% in 2023 and averaged 168.68%.
- As far as peak fluctuations go, Moderna's Net Margin soared by 16130400bps in 2021, and later plummeted by -7078400bps in 2024.
- Quarter analysis of 5 years shows Moderna's Net Margin stood at 67.51% in 2021, then tumbled by -57bps to 28.82% in 2022, then crashed by -73bps to 7.72% in 2023, then crashed by -1602bps to 115.94% in 2024, then skyrocketed by 83bps to 19.69% in 2025.
- Its last three reported values are 19.69% in Q3 2025, 580.99% for Q2 2025, and 899.07% during Q1 2025.